The April 3, 2015, issue of the prestigious journal Science is devoted to “realizing the promise” of cancer immunology and immunotherapy. Five separate review articles, whose list of authors reads like a Who’s Who of Cancer Research Institute (CRI) scientists, cover the main research areas and treatment approaches that currently excite the field, including:
Two additional research articles also discuss results of an anti-PD-1 checkpoint inhibitor in non-small cell lung cancer, co-authored by several CRI scientists, including our clinical director Jedd Wolchok of Memorial Sloan Kettering Cancer Center and lung cancer page reviewer Naiyer Rizvi of Columbia University Medical Center, and advances in natural killer (NK) cell biology written by Weiwen Deng, a CRI postdoctoral fellow, and David Raulet, a CRI investigator award recipient, of UC-Berkeley.
Science is one of the world’s most respected scientific journals. In December 2013, the journal voted Cancer Immunotherapy the “Breakthrough of the Year.”
What Ever Happened to Coley’s Toxins?
Read Previous Article
Science Special Issue
Read Next Article
*Immunotherapy results may vary from patient to patient.
Cancer Research Institute | National Headquarters
29 Broadway, Floor 4 | New York, NY 10006-3111
Dr. E. John Wherry dicusses cell therapies and the cancer ecosystem during Day 3 of the 2022 CRI-ENCI-AACR International Cancer Immunotherapy Conference (CICON22).
Drs. Stefani Spranger and Elsa Anagnostou recap highlights relating to myeloid cells, tumor heterogeneity, and preclinical models from Day 2 of of the 2022 CRI-ENCI-AACR International Cancer Immunotherapy Conference (CICON22).